Abstract
Regulation of the cysteine transporter known as excitatory amino acid carrier-1 (EAAC1) for intracellular glutathione (GSH) content was investigated using human embryonic kidney (HEK) 293 cells as a model system. GSH content was significantly reduced by l-aspartate-β-hydroxamate (50–250 μM), an inhibitor of both EAAC1 and GLT1, both of which are transporters to take up cysteine, whereas dihydrokainate (1–100 μM), a specific inhibitor of GLT1, failed to do so. This indicates that EAAC1 is involved in GSH content in HEK293 cells. We examined the effect of glutamate transport-associated protein 3-18 (GTRAP3-18), which is capable of interacting with EAAC1. The GSH content decreased when the GTRAP3-18 protein level at the plasma membrane was increased by methyl-β-cyclodextrin (250 μM), rendering the cells more vulnerable to oxidative stress. Intracellular GSH increased when the GTRAP3-18 protein level at the plasma membrane was decreased by antisense oligonucleotides, rendering the cells more resistant to oxidative stress. Furthermore, we found that the increase in GSH content produced by stimulating protein kinase C, a translocator and activator of EAAC1, was inhibited by an increase in cell surface GTRAP3-18 protein. These results show GTRAP3-18 to negatively and dominantly regulate cellular GSH content via interaction with EAAC1 at the plasma membrane.
Footnotes
-
This work was supported in part by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology.
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.107.039461.
-
ABBREVIATIONS: GSH, glutathione; HEK, human embryonic kidney; EAAC1, excitatory amino acid carrier-1; EAAT, excitatory amino acid transporter; GTRAP3-18, glutamate transport-associated protein for EAAC1; LAβH, l-aspartate-β-hydroxamate; MeβCD, methyl-β-cyclodextrin; PMA, 4β,9α,12β,13α,20-pentahydroxytiglia-1,6-dien-3-one 12-tetradecanoate 13-acetate; 4α-PMA, 4α,9α,12β,13α,20-pentahydroxytiglia-1,6-dien-3-one 12-tetradecanoate 13-acetate; TBOA, dl-threo-β-benzyloxyaspartate; DHK, dihydrokainate.
- Received June 27, 2007.
- Accepted July 23, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|